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Sapto Yuliani 1, Mustofa 2, Ginus Partadiredja 3
1Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia, 2Department of Pharmacology and
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Introduction: Oxidative stress is known to contribute to the pathogenesis of neurodegenerative disorders.
An ethanolic turmeric (Curcuma longa L.) extract containing curcumin has been reported to produce
antioxidant effects.
Objective: The present study aims to investigate the possible neuroprotective effects of the ethanolic turmeric
extract against trimethyltin (TMT)-induced oxidative stress in Sprague Dawley rats.
Methods: The ethanolic turmeric extract and citicoline were administered to the TMT exposed rats from day 1
to day 28 of the experiment. The TMT injection was administered on day 8 of the experiment. The plasma and
brain malondialdehyde (MDA) and reduced glutathione (GSH) levels, and the activities of the superoxide
dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx) enzymes in the brain were examined
at the end of the experiment.
Results: The administration of 200 mg/kg bw of the ethanolic turmeric extract prevented oxidative stress by
decreasing the plasma and brain MDA levels and increasing the SOD, CAT, and GPx enzyme activities and
GSH levels in the brain. These effects seem to be comparable to those of citicoline.
Discussion: The ethanolic turmeric extract at a dose of 200 mg/kg bw may exert neuroprotective effects on
TMT-exposed Sprague Dawley rats by preventing them from oxidative stress.
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Introduction
Oxidative stress, which is an imbalance between reac-
tive oxygen species (ROS) production and elimination
by the antioxidant defense system, is considered to
underpin the pathogenesis of neurodegenerative dis-
orders.1 Brain cells are very sensitive to oxidative
damage, due to the high oxygen demand of the
brain. Oxidative damage to lipids consisting of unsatu-
rated fatty acids (lipid peroxidation) yields end
products such as malondialdehyde (MDA), 4-
hydroxy-2,3-nonenal, acrolein, and other compounds2
that exert negative effects on human health.
Endogenous antioxidant enzymes, such as gluta-
thione peroxidase (GPx), superoxide dismutase
(SOD), and catalase (CAT), serve to protect the cells
from the oxidative damage.3 However, while the unsa-
turated fatty acid content of the brain is high, the
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antioxidant defense system of the brain is weaker com-
pared to that of other organs. Therefore, oxidative
stress may easily cause the degeneration of the hippo-
campus, a major brain region for memory processing.
In turn, such degeneration may play a role in the
pathogenesis of neurodegenerative disorders, includ-
ing dementia.4
Trimethyltin (TMT) is an organometal that has neu-
rotoxic effects. TMT enhances the formation of ROS
in the hippocampus. TMT also increases the
expression of important factors related to the patho-
physiology of Alzheimer’s disease (AD) such as
amyloid precursor protein, presenilin and c-fos in the
limbic system.5 Therefore, TMT-intoxicated rats may
serve as valuable models for studies of neurodegenera-
tive disorders, such as Alzheimer’s disease.6
Curcuma longa, L. or turmeric is widely known as a
dietary food ingredient and traditionally used as amed-
icinal herb. The potential use of turmeric as an alterna-
tive medicine is attributed to its antioxidant properties.
In vitro and in vivo studies showed that the active com-
pound of turmeric extract, curcumin, prevented oxi-
dative stress-induced neurodegeneration in the
nervous system.7,8 Our previous studies have shown
that an ethanolic turmeric extract prevented the deficits
of the spatialmemoryand the estimated total numberof
hippocampal pyramidal cells,9 as well as inhibited the
apoptosis of the pyramidal neurons in the CA2–CA3
region, but not in the CA1 region of the hippocampus
of TMT-exposed rats.10 The present study extends
these studies and aims to determine the effects of the
ethanolic extract of turmeric on the levels of oxidative
stress markers in the brains and plasma of Sprague
Dawley rats exposed to TMT. The effects of the tur-
meric extract were compared to those of citicoline (citi-
dine-5-diphosphocholine or CDP-choline) (an
endogenous compound that stabilizes membrane func-
tion and reduces free radical generation), which is a
drug of choice for dementia.
Methods
Animals
Thirty-six adult male Sprague Dawley rats weighing
approximately 195–215 g were obtained from the
animal house of Universitas Gadjah Mada. The
animals were housed individually in cages under stan-
dard conditions (room temperature: 24–26°C; humid-
ity: 60–65%; 12/12-h natural light/dark cycle). The
animals had free access to food and water. The rats
were acclimatized for at least 6 days prior to the
study. The experimental protocols and animal hand-
ling procedures were approved by the Ethics
Committee of the Integrated Research and Testing
Laboratory, Universitas Gadjah Mada (approval
number 130/KEC-LPPT/XII/2013).
Extraction of the turmeric rhizome
The turmeric rhizome was obtained from CV. Merapi
Farma, Yogyakarta, Indonesia, and verified by a bota-
nist from the Department of Biology, Universitas
Ahmad Dahlan, Yogyakarta, Indonesia. The extract
was prepared as follows: five hundred grams of the tur-
meric rhizome powder were macerated in 1.25 l of 96%
ethanol (Merck, Darmstat, Germany). The macera-
tion was repeated twice, followed by filtration. The
resulting filtrate was concentrated using a vacuum
rotary evaporator (Heidolph, Schwabach, Germany)
under reduced pressure at 40°C. The final yield of
the turmeric extract was 30.38% w/w. The concen-
tration of curcumin that represented the major active
content of the extract was determined using a TLC
scanner densitometer (CAMAG, Muttenz,
Switzerland) operated at a wavelength of 426 nm.
The curcumin level obtained was 28.08%. The tur-
meric rhizome extract was finally dissolved in a
sodium-carboxymethyl cellulose (CMC-Na) solution
prior to oral administration to the rats.
Experimental design
The rats were randomly divided into six groups as
follows: the N group served as a normal or vehicle
group and was treated with the CMC-Na solution
(the vehicle of turmeric extract) and an intraperitoneal
injection of 0.9% saline; the T group served as control
group and was orally administered the CMC-Na sol-
ution and intraperitoneally injected with TMT chlor-
ide (Sigma-Aldrich, Inc., St. Louis, Mo, USA)
dissolved in 0.9% saline;11 the T-Cit group served as
a positive control group and was orally administered
200 mg/kg bw of a citicoline solution (Bernofarm
Pharmaceutical Company, Sidoarjo, Indonesia) and
injected with TMT chloride; and the T-TE100, T-
TE200, and T-TE300 groups, which were orally admi-
nistered 100, 200, and 300 mg/kg bw, respectively, of
the ethanolic extract of turmeric and intraperitoneally
injected with TMT chloride. The doses of the extract
adopted in the present study referred to the curcumin
doses applied in Awasthi et al.’s study.12 The curcumin
doses were converted into turmeric extract doses which
were considered acceptable for humans. Each group
consisted of six rats. The ethanolic extracts of turmeric
and the citicoline solutions were administered daily
from day 1 to day 28 of the experiment. The TMT
chloride injection was administered as a single dose
of 8 mg/kg bw on day 8 of the experiment. The tur-
meric extracts and the citicoline solutions were deliber-
ately administered daily for a week prior to the TMT
injection with the purpose to give a prophylactic pro-
tection to the rats. At day 36, the rats’ blood was
taken from the sinus orbitalis. These blood samples
were used to determine the plasma MDA levels.
Then, all rats were sacrificed and the cerebral
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hemispheres of the rats were dissected from their
skulls. The left cerebral hemispheres were homogen-
ized at 4°C using a homogenizer (Potter-Elvehjem
Tissue Grinders, Wheaton, IL, USA). The homogen-
ates were used for the biochemical assays. In the
present study, the cerebral hemispheres were used for
the experiment since in the brain of AD patients, oxi-
dative stress products are found not only in the hippo-
campus but also in other regions of the brain such as in
the temporal lobe.13
Experimental procedures
Measurement of the plasma MDA levels
The plasma MDA levels were measured using a pre-
viously described method.14 Briefly, 0.75 ml of phos-
phoric acid was poured into a tube filled with
0.25 ml of thiobarbituric acid (TBA) (Sigma Aldrich,
Inc.). Subsequently, 0.05 ml of the blood plasma and
0.45 ml of water were added to the tube, and this
mixture was blended with a vortex for 2 minutes.
The mixture was then heated in a water bath
(Memmert, Germany) for 60 minutes at 60°C. After
being cooled for 1–2 hours, the mixture was poured
into a Sep-Pak C18 (Waters) column to bind with
MDA and washed with 5 ml of methanol and water.
The absorbance of the mixture was examined using a
spectrophotometer (Shimadzu – 1601, Kyoto, Japan)
at a wavelength of 532 nm. The absorbance of the
mixture was compared with that of a 1,1,3,3-tetra-
ethoxypropane (TEP) solution (Sigma Aldrich, Inc.),
which served as a standard. The MDA values were
expressed as mmol/l plasma.
Measurement of the brain MDA levels
The brain MDA levels were determined according to
the method described in the study by Colado et al.15
Five hundred microliters of the tissue homogenate dis-
solved in phosphate buffer solution (pH 7.4) were
mixed with 300 μl of 30% trichloroacetic acid, 150 μl
of 5 N HCl, and 300 μl of 2% w/v TBA. The
mixture was heated at 90°C for 15 minutes and centri-
fuged at 12 000 g for 10 minutes. The absorbance of
the supernatant was read in a spectrophotometer at a
wavelength of 532 nm. 1,1,3,3-TEP was used as a stan-
dard. The MDA level was expressed as nmol/mg
tissue.
Measurement of the brain SOD activity
The SOD activity in the brain tissues was determined
using an Assay Kit, Cat. K335-100 (BioVision,
Milpitas, CA, USA). The tissues were homogenized
in 0.2 ml of 0.1 M Tris/0.1 M HCl (pH 7.4) and cen-
trifuged at 14 000 rpm for 5 minutes at 4°C. The super-
natants of these mixtures were used to measure the
activity of the SOD enzyme. Three blank solution
wells were used for each sample. Twenty microliters
of supernatant were added to the sample well and
blank well 2. Meanwhile, 20 µl of distilled water were
added to blank wells 1 and 3. At the same time,
200 µl of working solution were added to each well
and 20 µl of buffer solution were added to blank
wells 2 and 3. Twenty microliters of the enzyme sol-
ution were added into each of the wells and the
mixture was homogenized by wrapping the microplate
with aluminum foil and shaking it. These mixtures
were then incubated at 37°C for 20 minutes. The
absorbance of these mixtures was measured at a wave-
length of 450 nm using a microplate reader (Bio-Rad
model 680 XR, California, USA). The SOD activity
was normalized to the milligrams of protein used in
the assay and expressed as ng/mg protein.
Measurement of the brain CAT activity
The CAT enzyme activity in the tissues was deter-
mined using an Assay Kit, Cat. K773-100
(BioVision). In this assay, CAT first reacts with
H2O2 to produce water and oxygen. The unconverted
H2O2 reacts with an OxiRed™ probe to produce water
and oxygen. This reaction is assessed by a colorimetric
method. Briefly, the brain tissue homogenates were
centrifuged at 10 000 rpm for 15 minutes at 4°C in
cold assay buffer, and the supernatants were collected
for the assay. The assay was performed in triplicate
using 96-well microplates. The rate of H2O2 decompo-
sition was measured at a wavelength of 570 nm in a
microplate reader (model 680 XR, Bio-Rad
Laboratories). One unit of CAT was defined as the
amount of enzyme needed to decompose 1 μM of
H2O2 in 1 min. The CAT activity was normalized to
the milligrams of protein used in the assay and
expressed as mU/mg protein.
Measurement of the brain reduced glutathione levels
The GSH content of the brain tissues was analyzed
using a colorimetric GSH detection kit according to
the manufacturer’s instructions (Cat. K261-100,
BioVision). One hundred milligrams of the brain
tissue homogenates dissolved in 0.4 ml of glutathione
(GSH) buffer were mixed with 100 μl of 5% SSA and
centrifuged at 8000 rpm for 10 minutes. The super-
natant of the mixture was transferred into a fresh
tube and used for the GSH assay. One hundred sixty
microliters of a reaction mixture containing the
NADPH generating mix, GSH reductase, and GSH
reaction buffer was added to 96-well plates and incu-
bated at room temperature for 10 minutes to generate
NADPH. Twenty microliters of either the GSH stan-
dard solutions or the supernatant was pipetted into
the wells, and the plates were incubated at the room
temperature for 10 minutes. The GSH concentrations
in the sample solutions were calculated using the stan-
dard GSH calibration curve and expressed as µg/mg
protein.
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Measurement of the brain GPx activity
The GPx activity was determined using an assay kit
(Cat. K762-100, BioVision) according to the manufac-
turer’s instructions. Approximately 0.1 g of the brain
tissue homogenates dissolved in 0.2 ml cold assay
buffer was centrifuged at 10 000 rpm for 15 minutes
at 4°C. The supernatant of this mixture was collected
and used for the assay. Ten microliters of the super-
natants were transferred into 96-well plates. Forty
microliters of reaction mix (containing 33 µl of assay
buffer, 3 μl of a 40 mM NADPH solution, 2 μl of
GR solution and 2 μl of GSH solution) were added
to the plates to deplete the GSSG in the samples and
this mixture was incubated for 15 minutes. Ten micro-
liters of a cumene hydroperoxide solution were added
to the mixture to start the GPx reaction. The GPx
activity was measured at a wavelength of 340 nm at 5
and 140 minutes. The NADPH levels were calculated
based on a standard curve. The GPx activity was
expressed as mU/mg protein.
Estimation of the brain protein concentrations
The brain protein concentrations were determined
using a biuret method. One hundred milligrams of
the brain homogenates were mixed with 0.4 ml of dis-
tilled water and centrifuged at 8000 rpm for 15
minutes. Forty microliters of the supernatant of this
mixture were pipetted into tubes and distilled water
was added until the volume of the mixture reached
150 µl. The mixture was then mixed with 100 µl of
biuret reagent and incubated at the room temperature
for 30 minutes. The absorbance of this mixture was
measured at a wavelength of 540 nm using a micro-
plate reader (model 680 XR, Bio-Rad Laboratories).
The protein concentrations were calculated based on
a standard curve and expressed as mg/ml.
Statistical analyses
All datawere tested using the Shapiro–Wilk and Levene
tests for the normality and homogeneity of the data,
respectively. When the data were normally distributed
and homogenous, the data were analyzed using one-
way ANOVA, followed by the post hoc Tukey’s HSD
test. When the data were not normally distributed or
homogenous, they were analyzed using the Kruskal–
Wallis test, followed by the Mann–Whitney U test.
All data were analyzed using SPSS software version
21. The significance level was set at P< 0.05.
Results
Figures 1–6 present the data for the plasma MDA and
brain MDA and GSH levels, as well as the SOD, CAT,
and GPx enzyme activities. The injection of a single
dose of 8 mg/kg bw of TMT in the T group signifi-
cantly increased the plasma (P= 0.002) and brain
MDA (P= 0.002) levels and decreased the activities
of the SOD (P= 0.004), CAT (P= 0.0001), and GPx
(P= 0.002) enzymes and the level of GSH (P=
0.002) in the brain compared to the N group.
The administration of 100 mg/kg bw of the ethano-
lic turmeric extract to the TMT-injected rats (T-
TE100) significantly decreased the plasma MDA
levels, but not the brain MDA levels. However, this
dose of the ethanolic turmeric extract failed to
reverse the TMT-induced decrease in the activities of
the SOD (P= 0.132), CAT (P= 0.466), and GPx
(P= 0.310) enzymes and GSH levels (P= 0.602) in
the rats’ brains.
The administration of 200 mg/kg bw of the ethanolic
turmeric extract to the TMT-injected rats (T-TE200)
significantly decreased the plasma (P= 0.002) and
brain (P= 0.002) MDA levels. The activities of the
Figure 1. Comparison of the plasma MDA levels in the
normal (N), control TMT (T), Citicoline (T-Cit), 100 mg/kg bw
of the ethanolic turmeric extract (T-TE100), 200 mg/kg bw of
the ethanolic turmeric extract (T-TE200), and 300 mg/kg bw
the ethanolic turmeric extract (T-TE300) groups of Sprague
Dawley rats exposed to TMT. The values are expressed as the
means± SEM of each group (n= 6). *P< 0.05, compared to
the T group; #P< 0.05, compared to the N group;
Kruskal–Wallis test, followed by the Mann–Whitney U test.
Figure 2. Comparison of the brain MDA levels in the normal
(N), control TMT (T), Citicoline (T-Cit), 100 mg/kg bw of the
ethanolic turmeric extract (T-TE100), 200 mg/kg bw of the
ethanolic turmeric extract (T-TE200), and 300 mg/kg bw of
the ethanolic turmeric extract (T-TE300) groups of Sprague
Dawley rats exposed to TMT. The values are expressed as the
means± SEM of each group (n= 6). *P< 0.05, compared to
the T group; #P< 0.05, compared to the N group;
Kruskal–Wallis test, followed by the Mann–Whitney U test.
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SOD, CAT, and GPx enzymes and GSH levels in the
brain were significantly increased after the adminis-
tration of 200 mg/kg bw of the ethanolic turmeric
extract (P= 0.015; P= 0.045; P= 0.015; and P=
0.015, respectively) compared to the T group.
The administration of 300 mg/kg bw of the tur-
meric extract decreased the plasma MDA levels (P=
0.002), but not the brain MDA levels, in the TMT-
injected rats (T-TE300). This dose of the ethanolic
turmeric extract was not able to prevent the TMT-
induced decrease in the SOD, CAT, and GPx
enzyme activities and GSH levels compared to the T
group.
The administration of 200 mg/kg bw of citicoline to
the TMT-injected rats (T-Cit) decreased the plasma
(P= 0.002) and brain (P= 0.002) MDA levels. The
current dose of citicoline also significantly increased
the activities of the SOD (P= 0.002), CAT (P=
0.006), and GPx (P= 0.002) enzymes in the rats’
brains compared to the T group. There was no signifi-
cant difference in the GSH levels between the T-Cit
and N groups (P= 0.070) or between the T-Cit and
T groups (P= 0.117).16
Discussion
In the present study, we found that rats injected with a
single dose of TMTexhibited an increase in the plasma
and brain MDA levels and a decrease in the activities
of antioxidant enzymes (SOD, CAT, and GPx) and the
levels of a non-enzymatic antioxidant co-factor
(GSH). TMT is a potent neurotoxicant that can
Figure 3. Comparison of the brain SOD activity in the normal
(N), control TMT (T), Citicoline (T-Cit), 100 mg/kg bw of the
ethanolic turmeric extract (T-TE100), 200 mg/kg bw of the
ethanolic turmeric extract (T-TE200), and 300 mg/kg bw of
the ethanolic turmeric extract (T-TE300) groups of Sprague
Dawley rats exposed to TMT. The values are expressed as the
means± SEM of each group (n= 6). *P< 0.05, compared to
the T group; #P< 0.05, compared to the N group;
Kruskal–Wallis test, followed by the Mann–Whitney U test.
Figure 4. Comparison of the brain CAT activity in the normal
(N), control TMT (T), Citicoline (T-Cit), 100 mg/kg bw of the
ethanolic turmeric extract (T-TE100), 200 mg/kg bw of the
ethanolic turmeric extract (T-TE200), and 300 mg/kg bw of
ethanolic turmeric extract (T-TE300) groups of Sprague
Dawley rats exposed to TMT. The values are expressed as the
means± SEM of each group (n= 6). *P< 0.05, compared to
the T group; #P< 0.05, compared to the N group; one-way
ANOVA test, followed by Tukey’s HSD test. F5, 30= 7.533; P<
0.05.
Figure 5. Comparison of the brain GSH levels in the normal
(N), control TMT (T), Citicoline (T-Cit), 100 mg/kg bw of the
ethanolic turmeric extract (T-TE100), 200 mg/kg bw of the
ethanolic turmeric extract (T-TE200), and 300 mg/kg bw of
the ethanolic turmeric extract (T-TE300) groups of Sprague
Dawley rats exposed to TMT. The values are expressed as the
means± SEM of each group (n= 6). *P< 0.05, compared to
the T group; #P < 0.05, compared to the N group; one-way
ANOVA, followed by Tukey’s HSD test. F5, 30= 4.214; P< 0.05.
Figure 6. Comparison of the GPx activity in the normal (N),
control TMT (T), Citicoline (T-Cit), 100 mg/kg bw of the
ethanolic turmeric extract (T-TE100), 200 mg/kg bw of the
ethanolic turmeric extract (T-TE200), and 300 mg/kg bw of
the ethanolic turmeric extract (T-TE300) groups of Sprague
Dawley rats exposed to TMT. The values are expressed as the
means± SEM of each group (n= 6). *P< 0.05, compared to
the T group; #P < 0.05, compared to the N group;
Kruskal–Wallis test, followed by the Mann–Whitney U test.
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induce severe damage and neuronal death in both the
human and animal limbic system, particularly in the
hippocampus. TMT is currently regarded as a useful
tool to obtain an animal model of neurodegeneration
associated with cognitive impairment, such as demen-
tia. However, the precise mechanisms of its effects are
not entirely clear.17 In general, it is thought that the
toxicity of organotin compounds is related to the
number and length of the alkyl groups attached to the
tin atom. Its toxicity also depends on the compound’s
affinity for neurons.18 Previous studies reported that
TMT-induced neuronal damage was mediated by
derivatives of ROS and reactive nitrogen species. At
high concentrations, ROS, such as hydrogen peroxide
(H2O2), superoxide anion (O2•−), and hydroxyl
radical (HO•), can be important mediators of damage
to cell structures, including peroxidation of lipids, oxi-
dation of proteins, damage to nucleic acids, and
enzyme inhibition.19 In hippocampal cells, TMT
intoxication increased membrane lipid peroxidation,
ultimately leading to cell death. This impact of oxi-
dative stress has been found to be implicated in a wide
range of neurological disorders including stroke,
trauma, and dementia.20
The 200 mg/kg bw dose of the ethanolic turmeric
extract has been shown to exert the highest efficacy
compared to both the lower and higher doses exam-
ined in the current study. The administration of tur-
meric extract prior and subsequent to TMT exposure
has been shown to prevent the brain of rats from oxi-
dative stress. TMT produces delayed toxicity where the
most dramatic reduction of pyramidal cell numbers of
TMT-treated rats occurs between 14 and 28 days after
TMT injection.21 In this study, the preventive effect of
turmeric extract was evidenced by the decrease of the
plasma and brain MDA levels and by the increase of
the CAT, GPx, and SOD enzyme activities and GSH
levels in the TMT-injected rats. All parameters were
measured at the end of the experiment.
It is well known that curcumin, the major com-
pound of the ethanolic turmeric extract, is capable of
attenuating the production of ROS and neutralizing
harmful free radicals such as superoxide anions,
hydroxyl radicals, and nitric oxide.22 The phenolic
and the methoxy groups on the phenyl ring appear
to be important structural features for these
actions.23 Curcumin induces endogenous antioxidant
defense mechanisms by modulating nuclear factors
such as E2-related factor 2 (Nrf2),24 activator
protein-1, and nuclear factor kappa B (NFκB). This
in turn implicates the expression of a variety of genes
in response to oxidative stress.25 Phosphorylation of
Nrf2 allows the Nrf2 to translocate to the nucleus
and bind to the antioxidant response element in the
regulatory region of the target genes and induces the
transcription of antioxidant enzymes.26
Pre-clinical studies have shown that orally delivered
curcumin has neuroprotective effects27 and has been
found to reduce lipid peroxidation by maintaining
the activities of antioxidant enzymes such as CAT,
SOD, GPx, and GSH levels in rats exposed with neu-
rotoxic compounds.28,29 The ability of curcumin to
increase the GSH levels is due to its affinity to
induce the transcription of the mRNAs for the GSH
biosynthetic genes.30 Clinical studies also demon-
strated that oral curcumin remarkably improved the
behavioral symptoms of patients with AD31 and ame-
liorated systemic oxidative stress on human with
chronic pulmonary complication.32
The particular method of preparation of curcumin
may enhance the above-mentioned beneficial effects
of curcumin. Curcumin emulsified in CMC has a
potent anti-inflammatory effect.33 Curcumin in its dis-
solved or emulsified form has been shown to be easily
absorbed in the gastrointestinal system of rats.34
Furthermore, curcumin administrated orally is con-
sidered to cross the blood–brain barrier as shown in
a multi-photon microscopy study on in vivo
Alzheimer’s model of mice.35 However, in the
present study, it remains uncertain whether the recon-
stituted turmeric actually crossed the blood–brain
barrier, since we used turmeric extract instead of cur-
cumin, and applied a different method of dissolution
from that of Cui et al and Garcia-Alloza et al’s
studies.34,35 Further investigation on the pharmacoki-
netics of turmeric extract is required to determine the
bioavailability of curcumin in both the brain and
plasma.
The present study did not observe a linear dose–
response relationship between the effects of the etha-
nolic turmeric extract on TMT-induced oxidative
stress. The higher doses of the ethanolic turmeric
extract (300 mg/kg bw) did not correspond to
increased activity of the extract. This may be due to
paradoxical effects of curcumin, which can act as an
antioxidant or pro-oxidant, depending on the concen-
tration and the cellular environment.36 The pro-
oxidant activities appear to be mediated by the
generation of phenoxyl radical of curcumin by the per-
oxidase–H2O2 system, which co-oxidizes cellular GSH
or NADH to form ROS.37 Curcumin-mediated apop-
tosis is closely related to the increase in the intracellu-
lar ROS levels. The exact dose of curcumin that can
cause the pro-oxidative effects remains to be
determined.
The antioxidant activities of the 200 mg/kg bw dose
of the turmeric extract seem to resemble those of citi-
coline in several parameters (plasma and brain MDA
levels; SOD, GPx, and CAT enzyme activities).
Citicoline is commonly used as a neuroprotective
and memory enhancing agent.38 In this study, this
drug was shown to reduce the plasma and brain
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MDA levels, as well as to increase the levels of GSH
and the GPx, SOD, and CAT enzyme activities in
the brains of rats exposed to TMT. Another study
reported that citicoline stimulated the biosynthesis of
GSH, activated the GSH reductase enzyme, and pre-
vented lipid peroxidation.39
In summary, the ethanolic turmeric extract pre-
vented TMT-induced oxidative stress at a dose of
200 mg/kg bw by decreasing the plasma and brain
MDA levels and increasing the SOD, CAT, and GPx
enzyme activities as well as GSH levels in the brain.
These effects seem to be similar to those of citicoline.
Further studies are required to investigate the potential
use of this extract as a substitute treatment for neuro-
degenerative disorders.
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